Regorafenib, the CORRECT way forward or just another GRIDlock?

Studies carried out through the past few decades have increased our understanding of the molecular mechanisms behind colorectal cancer (CRC) and gastrointestinal stromal tumours (GIST). The identification of some of the mutations that drive these types of cancer (such as mutations in KIT or PDGFRA in GIST, and mutations in KRAS in CRC) has allowed the development of tyrosine kinase inhibitors (TKI) and antibodies that have provided numerous treatment options improving considerably the clinical outcomes of patients with these malignancies.